Diana Tichy

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Hartmut Goldschmidt, K. Elias, Uta Bertsch et al. · The Lancet Haematology · 2022 · 142 citations

Transplantation-eligible Patients, Hematological Malignancy, Part 1 +9

Prediction of malignancy by a radiomic signature from contrast agent‐free diffusion MRI in suspicious breast lesions found on screening mammography.

Sebastian Bickelhaupt, Daniel Paech, Philipp Kickingereder et al. · Journal of Magnetic Resonance Imaging · 2017 · 137 citations

Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla

Matthias Roethke, Timur H. Kuru, S. Schultze et al. · European Radiology · 2013 · 133 citations

Urology, Engineering, Multiparametric Mri +9

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Lisa Leypoldt, Diana Tichy, Britta Besemer et al. · Journal of Clinical Oncology · 2023 · 125 citations · Full text

Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set

Maria Bonsack, Stéphanie Hoppe, Jan Winter et al. · Cancer Immunology Research · 2019 · 87 citations